Dyania Health

We envision a future where healthcare is profoundly transformed by the seamless integration of artificial intelligence and clinical expertise, accelerating medical research and improving patient outcomes on a global scale.

At Dyania Health, we harness the power of advanced large language models to automate the complex extraction of clinical insights from electronic medical records, reducing time and manual effort while elevating accuracy and compliance.

Our mission is to enable healthcare systems and pharmaceutical innovators to unlock the full potential of their data, driving new possibilities in clinical trials, patient care, and real-world evidence generation for a healthier tomorrow.

We've been tracking Dyania Health since their early days, and honestly? They're tackling one of healthcare's most tedious problems in a surprisingly elegant way. While everyone else fights over flashy consumer health apps, this Jersey City startup is quietly revolutionizing how hospitals and pharma companies dig through mountains of medical records.

Founded in 2019 by CEO Eirini Schlosser, Dyania Health built something called Synapsis AI — essentially a super-smart assistant that can read through electronic medical records faster than any human ever could. We're talking about processing complex clinical questions in under 0.5 seconds, compared to the hours it typically takes medical experts to do the same work.

What Makes This Actually Useful

Here's where it gets interesting: Synapsis AI isn't just fast, it's genuinely intelligent about medical nuance. The platform can handle both structured data (the neat, organized stuff) and unstructured notes (those messy doctor scribbles that make up most medical records). It works across multiple disease areas — oncology, cardiology, autoimmune disorders — without needing separate training for each specialty.

The real kicker? It's helping solve clinical trial recruitment, which is notoriously slow and expensive. Instead of manually combing through records to find eligible patients, healthcare systems can now pre-screen candidates in real-time. That's a game-changer for both research timelines and patient access to cutting-edge treatments.

The Numbers That Caught Our Attention

Dyania Health already covers approximately 40 million patient lives across the U.S. — that's substantial reach for a five-year-old company. Their recent $10 million Series A (led by HealthX Ventures) brings their total funding to over $15 million, which feels right-sized for their current stage and ambitions.

We also appreciate that they're medically validated with full-time physicians on staff. Too many health tech companies skip this crucial step, but Dyania Health clearly understands that accuracy in healthcare isn't optional.

Who This Really Serves

While the technology is impressive, we think Dyania Health's sweet spot is large healthcare systems and pharmaceutical companies drowning in data processing costs. If you're spending millions on manual chart reviews (and most large health systems are), this platform could deliver serious ROI pretty quickly.

The HIPAA and GDPR compliance is table stakes, but their focus on real-time processing and disease-agnostic capabilities sets them apart from more narrow solutions. Plus, CEO Eirini Schlosser just made Inc.'s Female Founders 500 list for 2025 — always encouraging to see strong leadership getting recognized in this space.